Tags : Malignant Tumors

Biosimilars Biotech

Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar)

Shots: The BLA is based on two P-III study results assessing efficacy, safety and PK of IBI-305 vs bevacizumab in patients with advanced non-sq NSCLC and has demonstrated in meeting 1EPs with bio-similarity Innovent has received three NMPA acceptance including IBI-305 namely Tyvyt (sintilimab injection) and IBI-303 (adalimumab, biosimilar) in H2’18 for ankylosing spondylitis (AS), […]Read More